Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate.
about
HCV Kinetic Models and Their Implications in Drug DevelopmentGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignViral kinetic modeling: state of the artCuring a viral infection by targeting the host: the example of cyclophilin inhibitorsHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyModelling hepatitis C therapy--predicting effects of treatmentLamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in PatientsExceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus InfectionHepatitis C virus: Promising discoveries and new treatmentsMechanisms of viral mutationElucidation of hepatitis C virus transmission and early diversification by single genome sequencingA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionExtremely High Mutation Rate of HIV-1 In VivoViral diversity and clonal evolution from unphased genomic data.Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modellingEstimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.Generation and characterization of influenza A viruses with altered polymerase fidelity.Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinIdentification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplificationSingle-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification.Rapid hepatitis C virus divergence among chronically infected individuals.Hepatitis C viral kinetics: the past, present, and future.Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.Metabolomics technology and their application to the study of the viral infection.Issues in vaccinology: Present challenges and future directions.Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Modeling Viral Spread.Highly heterogeneous mutation rates in the hepatitis C virus genome.Different rates of spontaneous mutation of chloroplastic and nuclear viroids as determined by high-fidelity ultra-deep sequencing.Similarities between Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Genetic and Phenotypic Protease Quasispecies Diversity.Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014The external domains of the HIV-1 envelope are a mutational cold spot.
P2860
Q26801602-8EA1CB2C-12DF-405C-A7E0-F1E966B2868AQ26801759-7C232A57-A029-4537-9F4C-7053BE4E3A06Q26824655-B6841CA4-97ED-4C3A-B50E-DFF8A08AD7EDQ26828727-F19B7BB0-C5FB-40F6-B325-F7469CFE788EQ26853500-486D084C-CBFD-4AA8-BC57-1266C674B7C9Q26864673-9464282A-BFD5-48C3-ABE2-B2A74D60B64FQ27468616-6FBDE3DF-05F0-4884-B999-013E0171C450Q27468696-4525B103-89DE-4A94-9AED-70E45E4A87B0Q27468916-79B8B56F-8059-43DC-9846-D62676AD0070Q28067235-5B6D324E-8C77-4A06-9A43-54242574441BQ28482493-1A2EF68A-AAFC-4993-A240-74327E5FA54CQ28537708-260EDB3F-D3CA-4BC6-A92F-7277A20429A5Q28545971-B592B314-C1BF-4BCC-94CC-41AFF7701674Q28548089-E99B9909-AE0C-451E-A80F-04D6A4076C01Q30370595-412A1632-EF8A-4480-84E7-A34E17893831Q30583856-4BF83389-1588-4FBC-9793-BDB6E84BBB5DQ33629597-27C73FCB-2656-4A09-996B-FCA2ACCBDD46Q34137544-B9C890C3-B1F9-4D27-9D8F-6D551F5995F0Q34504820-CA136CB9-24E4-4935-8389-FF1AA468ADFEQ34594986-0741519A-276E-4E11-89D1-E3AA6E027D55Q34802167-BC86DA92-8D03-4BC9-BA4C-83C590C0B583Q35172385-6F40F7CA-26FC-428A-8C00-C76FC352C507Q36158391-08A4ECF2-1EA5-482C-8B53-2A99787EC015Q36330328-618D6B6B-2767-4D4E-8152-BCB51943B75DQ36433960-DC481476-BE70-44A6-B102-593677725E7FQ36558964-464D2D2D-0A15-44FF-AE91-92BDCE347C19Q36645517-BA51E04D-E444-44E6-AD20-F3987A5063CEQ36837502-993DF65C-9794-47B7-94B6-C67CB40CE58FQ38256890-81E2B28C-8C20-400D-A16D-73BF9FC8A55BQ38634551-40C86F5E-2900-401C-A525-5D29A7900203Q38735317-0259D4FF-7CE1-497C-85F8-703CA86B5BCAQ38735359-FEE0986D-1449-444F-9EE2-411608FDEA57Q38826176-5F303AAF-8D40-4C9E-9861-90B77B1CF560Q38849307-BAADDE9F-A8B3-4E27-9C4A-D24BFFF57EE9Q38952060-883B6E59-B44E-457E-AC2B-0A2CD42AE8B1Q39442707-16E5643D-AC28-4B0E-9FDB-F5FA51F5D064Q40041222-A58BA916-13FE-449B-B9FF-C5F96106D6A9Q40732189-A3E6376B-2E89-4EEA-AC17-B80F1B36CDD7Q40858663-1085C879-782F-4803-9686-201244B76D94Q40960413-1D140D84-FABB-4149-B903-9EDA374B6184
P2860
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Quantifying the diversificatio ...... of the in vivo mutation rate.
@ast
Quantifying the diversificatio ...... of the in vivo mutation rate.
@en
Quantifying the diversification of hepatitis C virus
@nl
type
label
Quantifying the diversificatio ...... of the in vivo mutation rate.
@ast
Quantifying the diversificatio ...... of the in vivo mutation rate.
@en
Quantifying the diversification of hepatitis C virus
@nl
prefLabel
Quantifying the diversificatio ...... of the in vivo mutation rate.
@ast
Quantifying the diversificatio ...... of the in vivo mutation rate.
@en
Quantifying the diversification of hepatitis C virus
@nl
P2093
P2860
P50
P1433
P1476
Quantifying the diversificatio ...... of the in vivo mutation rate.
@en
P2093
Erica H Parrish
Gerald H Learn
Mark B Stoddard
Shuyi Wang
P2860
P304
P356
10.1371/JOURNAL.PPAT.1002881
P50
P577
2012-08-23T00:00:00Z